Treating PNH: Understanding Complement Inhibitors, Modes of Administration, and Coordinated Patient Care Needs : Episode 10
Opinion
Video
Investigational Therapies Paving New PNH Treatment Pathways
Dr Haumschild continues leading a discussion surrounding potential treatment advancements in the PNH landscape.
Video Player is loading.
Video content above is prompted by the following:
- Looking towards the future, what advancements do you anticipate in the treatment landscape for PNH and other complement-driven rare diseases, particularly in relation to investigational therapeutics targeting the alternative pathway?
Related Videos
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
Building Better Collaboration: Reducing Care Delays in Managing mCRC
Best Practices for Overcoming mCRC Prior Authorization Barriers
Introduction to IgA Nephropathy
Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
Data Suggest ASCVD Scores Overlook Atherosclerosis in Low, Borderline-Risk Patients: Anna Mueller, MD
ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach
New FINEARTS-HF Findings Provide Clarity on Balancing Risk and Benefit in HF, CKD
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
Related Content
